The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors.
 
Lilit Karapetyan
No Relationships to Disclose
 
Adam C. Olson
Research Funding - Reflexion Medical
 
William E. Gooding
No Relationships to Disclose
 
Riyue Bao
No Relationships to Disclose
 
Steven J. Chmura
Employment - Astellas Pharma (I)
Honoraria - Reflexion Medical
Consulting or Advisory Role - AstraZeneca
Research Funding - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - UptoDate article
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alphamab; Array BioPharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Compugen; CStone Pharmaceuticals; Eisai; EMD Serono; Incyte; Janssen; Merck; Mersana; Nektar; Novartis; Partner Therapeutics; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; Spring Bank; Synlogic; Tempest Therapeutics; Tesaro; TTC Oncology; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios; Array BioPharma; Astellas Pharma; Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals; Corvus Pharmaceuticals (Inst); EMD Serono; Immatics; Incyte (Inst); Kadmon; Macrogenics (Inst); Merck (Inst); Moderna Therapeutics; Nektar; Spring bank; Trishula Therapeutics; Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics